(sye toe MEH gah loe vye rus ih MUNE GLAW byoo lin) Brand: Cytogam
• CMV IG is made from human plasma (part of the blood) and may contain infectious agents (e.g., viruses) that can reason malady. Although CMV IG is screened, tested, and treated to reduce the possibility that it carries an infectious agent, it can still potentially transmit malady. Discuss with your doctor the risks and benefits of using CMV IG.
• Treatment with immune globulin commodity such as CMV IG has been associated with the development of kidney problems, sometimes resulting in kidney failure and/or death. Notify your doctor immediately if you develop decreased urination, sudden weight gain, fluid retention or swelling, or shortness of breath. These may be signs of kidney problems.
• Rare cases of aseptic meningitis syndrome (AMS) have been associated with the use of immune globulin commodity such as CMV IG. Notify your doctor immediately if you experience severe headache, neck stiffness, drowsiness, fever, eye sensitivity to easy, painful eye movements, and nausea or vomiting. These may be signs of AMS. Stopping treatment with the immune globulin has resulted in resolution of AMS without any lasting problems.
• Cytomegalovirus immune globulin (CMV IG) is a sterilized solution obtained from pooled human blood. It contains the immunoglobulins (or antibodies) to protect against infection from cytomegalovirus. Antibodies are substances in the blood that fight infections.
• CMV IG is used to help prevent infection by cytomegalovirus in people who receive an organ transplant.
• CMV IG may also be used for purposes another than those listed here.
• Do not use CMV IG without first talking to your doctor if you have
· kidney disease;
· diabetes;
· IgA deficiency; or
· a previous allergic reaction to other immune globulin product.
• You may not be able to use CMV IG, or you may require a dosage adjustment or particular monitoring during treatment.
• CMV IG is in the FDA pregnancy category C. This means that it is not known whether it will be deleterious to an unborn child. Do not use CMV IG without first talking to your doctor if you are pregnant or could become pregnant during treatment.
• It is not known whether CMV IG passes into breast milk. Do not use CMV IG without first talking to your doctor if you are breast-feeding a baby.
• Individuals over the age of 65 years may have an heighten risk of kidney problems with the use of CMV IG. Your doctor may prescribe a lower doze of the medicine or particular monitoring during treatment.
• CMV IG will be administered by intravenous (into a vein) injection by a healthcare provider in a hospital or clinic setting.
• Your doctor may want you to have blood trials or another forms of monitoring during treatment with CMV IG to monitor progress and side effects.
• Your healthcare provider will store CMV IG as directed by the manufacturer. If you are storing CMV IG at house, your healthcare provider will provide storage instructions.
• Contact your healthcare provider if a doze of CMV IG is missed.
• Search abnormal medical attention or contact your healthcare provider if an overdose of CMV IG is suspected.
• No information is accessible regarding an overdose of CMV IG.
• Do not receive vaccines that use live strains of the virus (e.g., mumps-and-rubella-mmr-vaccine-22822.htm'>measles, mumps, and rubella or MMR) during and for approximately three months next treatment with CMV IG. These vaccines may not work properly when CMV IG has been recently administered.
• CMV IG is made from human plasma (part of the blood) and may contain infectious agents (e.g., viruses) that can reason malady. Although CMV IG is screened, tested, and treated to reduce the possibility that it carries an infectious agent, it can still potentially transmit malady. Discuss with your doctor the risks and benefits of using CMV IG.
• Treatment with immune globulin commodity such as CMV IG has been associated with the development of kidney problems, sometimes resulting in kidney failure and/or death. Notify your doctor immediately if you develop decreased urination, sudden weight gain, fluid retention or swelling, or shortness of breath. These may be signs of kidney problems.
• Rare cases of aseptic meningitis syndrome (AMS) have been associated with the use of immune globulin commodity such as CMV IG. Notify your doctor immediately if you experience severe headache, neck stiffness, drowsiness, fever, eye sensitivity to easy, painful eye movements, and nausea or vomiting. These may be signs of AMS. Stopping treatment with the immune globulin has resulted in resolution of AMS without any lasting problems.
• Notify your doctor immediately if you experience a rare but serious allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or person; or hives) to CMV IG.
• Another smaller serious side effects may also occur. Upon injection of the medicine, some patients experience the next side effects:
· flushing or sweating;
· wheezing;
· muscle cramps;
· joint pain;
· nausea or vomiting; or
· fever or chills.
• Side effects another than those listed here may also occur. Conversation to your doctor about any side effect that seems unusual or that is especially bothersome. You may message side effects to FDA at 1-800-FDA-1088.
• Do not receive vaccines that use live strains of the virus (e.g., mumps-and-rubella-mmr-vaccine-22822.htm'>measles, mumps, and rubella or MMR) during and for approximately three months next treatment with CMV IG. These vaccines may not work properly when CMV IG has been recently administered.
• It is not known whether another medications will interact with CMV IG. Conversation to your doctor and pharmacist till taking any prescription or over-the-counter medicines, including herbal commodity during treatment with CMV IG.
• Your pharmacist has additional information about CMV IG written for health professionals that you may read.
Remember, hold this and all another medicines out of the reach of children, never share your medicines with others, and use this medicine only for the indication prescribed.
Disclaim: Each effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses external of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way must be construed to indicate that the drug or drug combination is safety, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the help of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.